Evotec and BMS sign eight-year neuro discovery deal
The two companies extend their ongoing partnership by a further eight years to discover treatments for neurodegenerative conditions.
The two companies extend their ongoing partnership by a further eight years to discover treatments for neurodegenerative conditions.
The two French-based companies announced a strategic collaboration at the end of last month (March 2023) that saw Galapagos’ employees working in the research and discovery departments and transferred across to the contract research organization (CRO).
The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.
Paid for and in partnership with Lonza Small Molecules
The push towards greater patient centricity sees the need to create more flexible formulation options to patients, which is where multiparticulate technology can offer solutions in drug development.